New weight loss drug candidate enters first human tests
Disease control
Not yet recruiting
This early-stage study tests a new drug called IBIO-600 in 32 overweight or obese adults. The main goal is to find a safe and tolerable dose by checking for side effects and how the drug moves through the body. Participants receive a single dose and are monitored closely. This is…
Phase: PHASE1 • Sponsor: iBio, Inc. • Aim: Disease control
Last updated May 09, 2026 09:53 UTC